Clinical Trials Logo

Clinical Trial Summary

This is a multi-center, open-label, preference study of two sublingual formulations of buprenorphine HCl, in opioid-dependent patients on buprenorphine maintenance therapy. The objectives of this study are to evaluate the overall preference between two buprenorphine sublingual formulations, after a switch from the marketed tablet (Subutex®) to the new fast dissolving tablet (FDT), in opioid-dependent patients with buprenorphine 8 mg or 16 mg daily maintenance therapy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01075971
Study type Interventional
Source Indivior Inc.
Contact
Status Completed
Phase Phase 2
Start date September 2005
Completion date November 2005

See also
  Status Clinical Trial Phase
Terminated NCT00772785 - Study of Probuphine in Patients With Opioid Dependence Phase 3
Completed NCT00591617 - Optimizing Outcomes Using Suboxone for Opiate Dependence N/A
Completed NCT00913484 - Disulfiram for Cocaine Abuse in Buprenorphine Treatment Phase 2
Completed NCT01262261 - Re-Treatment Study of Probuphine in Opioid Addiction Phase 3
Terminated NCT00269607 - Naltrexone Implants as Relapse Prevention Phase 2/Phase 3
Completed NCT00577005 - Efficacy of Levetiracetam in Cocaine-Abusing Methadone Maintained Patients Phase 2
Completed NCT01806389 - A Study of Breastfeeding in Buprenorphine Maintained Women N/A
Completed NCT00955162 - Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME") Phase 4
Completed NCT00727675 - Chronic Pain and Opioid Dependence Assessment and Treatment N/A
Completed NCT00742170 - Transdermal Electroacupuncture for Opioid Detoxification Phase 1/Phase 2
Completed NCT01114308 - A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction Phase 3
Completed NCT00877591 - Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications Phase 1